Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications
Current Oncology · 15.05.2023 · 30 (5) · 5003-5023
DOI: 10.3390/curroncol30050378 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 15.05.2023. Verfasst von Simon R Mucha und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Core Grant, Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract (Originalsprache)
Chimeric Antigen Receptor T (CAR-T) cell therapy has dramatically changed prognosis and treatment of relapsed and refractory hematologic malignancies. Currently the 6 FDA approved products target various surface antigens. While CAR-T therapy achieves good response, life-threatening toxicities have been reported. Mechanistically, can be divided into two categories: (1) toxicities related to T-cell activation and release of high levels of cytokines: or (2) toxicities resulting from interaction between CAR and CAR targeted antigen expressed on non-malignant cells (i.e., on-target, off-tumor effects). Variations in conditioning therapies, co-stimulatory domains, CAR T-cell dose and anti-cytokine administration, pose a challenge in distinguishing cytokine mediated related toxicities from on-target, off-tumor toxicities. Timing, frequency, severity, as well as optimal management of CAR T-cell-related toxicities vary significantly between products and are likely to change as newer therapies become available. Currently the FDA approved CARs are targeted towards the B-cell malignancies however the future holds promise of expanding the target to solid tumor malignancies. Further highlighting the importance of early recognition and intervention for early and late onset CAR-T related toxicity. This contemporary review aims to describe presentation, grading and management of commonly encountered toxicities, short- and long-term complications, discuss preventive strategies and resource utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
- Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
ORCID-Profile: Simon R Mucha
Förderung
- NCI NIH HHS
- Core Grant
- Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Zitieren
APA
Mucha, S. R., & Rajendram, P. (2023). Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications. Current Oncology, 30(5), 5003-5023. https://doi.org/10.3390/curroncol30050378
Vancouver
Mucha SR, Rajendram P. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications. Current Oncology. 2023;30(5):5003-5023. doi:10.3390/curroncol30050378
BibTeX
@article{Mucha2023,
author = {Mucha, Simon R and Rajendram, Prabalini},
title = {Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {5},
pages = {5003--5023},
doi = {10.3390/curroncol30050378}
}
EUVIMED